Top Markets
#1 Glidr Glidr +51.75%
#2 Akedo Akedo +48.99%
#3 DOVU DOVU +48.23%
#4 Velvet Velvet +40.95%
#5 Black Phoenix Black Phoenix +34.26%
#6 Cross Cross +20.75%
#7 Cysic Cysic +18.58%
#8 Perle Perle +18.18%
#9 Ο„emplar Ο„emplar +16.67%
#10 Ribbita by Virtuals Ribbita by Virtuals +15.67%
Coin of the day
Glidr Glidr
Settings
Language
ENGLISH
Currency
USD
Theme
Enveric Biosciences, Inc. Enveric Biosciences, Inc.

Enveric Biosciences, Inc.

ENVB
Rank in Stocks #38583
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse... Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Share Price
$1.52
Market Cap
$906.74K
Change (1 day)
0.58%
Change (1 year)
-88.60%
Country
US
Trade Enveric Biosciences, Inc. (ENVB)

Category

Healthcare
P/E ratio for Enveric Biosciences, Inc. (ENVB)
P/E ratio as of 2026 TTM: 0
According to Enveric Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Enveric Biosciences, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.